Pantuck, Allan J <br/><br/>
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)   
 - 240-53 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1524-9557 
<br/><br/><label>Standard No.: </label>10.1097/00002371-200405000-00009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>CD4 Antigens--biosynthesis<br/>CD8 Antigens--biosynthesis<br/>Cancer Vaccines--therapeutic use<br/>Cell Separation<br/>Clinical Trials as Topic<br/>Dose-Response Relationship, Drug<br/>Flow Cytometry<br/>Genetic Therapy--methods<br/>Genetic Vectors<br/>Humans<br/>Immunotherapy<br/>Interleukin-2--genetics<br/>Male<br/>Middle Aged<br/>Mucin-1--genetics<br/>Phenotype<br/>Prostatic Neoplasms--therapy<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Th1 Cells<br/>Time Factors<br/>Tumor Necrosis Factor-alpha--metabolism<br/>Up-Regulation<br/>Vaccinia virus--genetics